SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make ...

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer ...

Roche Holding shares rose 2.1% Wednesday after the Swiss drugmaker reported positive results from a new study of an ...

In a Phase 1 trial, women responded well to the novel vaccine. More research is needed to determine whether it can stop the ...

A new vaccine targeting triple-negative breast cancer (TNBC) has shown promising results in its first human clinical trial.

Jessie said she was diagnosed in March with early-stage breast cancer, a diagnosis that came just days before she was set to ...

Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple ...

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...

After decades of research, Phase 1 of a Cleveland Clinic study shows a breast cancer vaccine is safe and triggers an immune ...